Literature DB >> 11459638

In vitro and In vivo inhibition of LPS-stimulated tumor necrosis factor-alpha secretion by the gallotannin beta-D-pentagalloylglucose.

K S Feldman1, K Sahasrabudhe, M D Lawlor, S L Wilson, C H Lang, W J Scheuchenzuber.   

Abstract

The naturally occurring gallotannin beta-D-pentagalloylglucose (beta-PGG) decreases tumor necrosis factor-alpha (TNF-alpha) output from human peripheral blood mononucleocytes exposed to lipopolysaccharide (LPS) by as much as 90% (vs control) at approximately 5 microM concentration. A qualitatively similar but less pronounced effect ( approximately 50% decrease) was observed in the serum of rats dosed with both LPS and beta-PGG. These results may have relevance to therapies that target disease states characterized by an overproduction of TNF-alpha.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11459638     DOI: 10.1016/s0960-894x(01)00332-8

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Effects of methyl gallate and gallic acid on the production of inflammatory mediators interleukin-6 and interleukin-8 by oral epithelial cells stimulated with Fusobacterium nucleatum.

Authors:  Mi-Sun Kang; Hee-Sook Jang; Jong-Suk Oh; Kyu-Ho Yang; Nam-Ki Choi; Hoi-Soon Lim; Seon-Mi Kim
Journal:  J Microbiol       Date:  2010-02-04       Impact factor: 3.422

Review 2.  Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose.

Authors:  Jinhui Zhang; Li Li; Sung-Hoon Kim; Ann E Hagerman; Junxuan Lü
Journal:  Pharm Res       Date:  2009-07-02       Impact factor: 4.200

Review 3.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

4.  Gelatin tannate reduces the proinflammatory effects of lipopolysaccharide in human intestinal epithelial cells.

Authors:  Giuseppina Frasca; Venera Cardile; Carmelo Puglia; Claudia Bonina; Francesco Bonina
Journal:  Clin Exp Gastroenterol       Date:  2012-05-08

5.  The attenuating effects of 1,2,3,4,6 penta-O-galloyl-β-d-glucose on inflammatory cytokines release from activated BV-2 microglial cells.

Authors:  Patricia Mendonca; Equar Taka; David Bauer; Makini Cobourne-Duval; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2017-01-18       Impact factor: 3.221

6.  Natural product 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose is a reversible inhibitor of glyceraldehyde 3-phosphate dehydrogenase.

Authors:  Wen Li; Li-Ping Liao; Ning Song; Yan-Jun Liu; Yi-Luan Ding; Yuan-Yuan Zhang; Xiao-Ru Zhou; Zhong-Ya Sun; Sen-Hao Xiao; Hong-Bo Wang; Jing Lu; Nai-Xia Zhang; Hua-Liang Jiang; Kai-Xian Chen; Chuan-Peng Liu; Jie Zheng; Ke-Hao Zhao; Cheng Luo
Journal:  Acta Pharmacol Sin       Date:  2021-04-13       Impact factor: 7.169

7.  The attenuating effects of 1,2,3,4,6 penta-O-galloyl-β-d-glucose on pro-inflammatory responses of LPS/IFNγ-activated BV-2 microglial cells through NFƙB and MAPK signaling pathways.

Authors:  Patricia Mendonca; Equar Taka; David Bauer; Renee R Reams; Karam F A Soliman
Journal:  J Neuroimmunol       Date:  2018-09-11       Impact factor: 3.221

8.  Ethyl gallate induces apoptosis of HL-60 cells by promoting the expression of caspases-8, -9, -3, apoptosis-inducing factor and endonuclease G.

Authors:  Woong-Hyun Kim; Hyun-Ok Song; Hwa-Jung Choi; Ho-Il Bang; Du-Young Choi; Hyun Park
Journal:  Int J Mol Sci       Date:  2012-09-20       Impact factor: 6.208

9.  Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways.

Authors:  Se-Eun Jang; Supriya R Hyam; Jin-Ju Jeong; Myung Joo Han; Dong-Hyun Kim
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 9.473

10.  Antidiabetes and Anti-obesity Activity of Lagerstroemia speciosa.

Authors:  Guy Klein; Jaekyung Kim; Klaus Himmeldirk; Yanyan Cao; Xiaozhuo Chen
Journal:  Evid Based Complement Alternat Med       Date:  2007-12       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.